AURA News - Candlesense

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:AURA) BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to ...

Investor event

7 days ago

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)

How might the sentiment score of 30 translate into market expectations and potential price movement after detailed results are released? What are the potential downside risks if the Phase 3 trial fails to meet its primary endpoints? Are there any partnership, licensing, or acquisition updates that could influence Aura's market perception?

Earnings

28 days ago

Aura Announces Exercise of the Underwriters’ Option to Purchase Additional Shares

Will the increased share count affect institutional ownership limits or trigger any fund rebalancing? What is the likely impact on the company’s capital structure and debt‑to‑equity ratio? How might this transaction influence Aura’s valuation multiples compared to peers in the sector?

Financing

about 1 month ago